Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

India Equity Movers: Bharti Airtel, Ranbaxy, Reliance Industries

The following companies had unusual price changes in India trading. Stock symbols are in parentheses and share prices are as of the 3:30 p.m. close in Mumbai.

The Bombay Stock Exchange Sensitive Index, or Sensex, dropped 258.78, or 1.4 percent, to 18,210.58, the lowest in more than a month. The BSE 200 Index slid 1.4 percent to 2,249.40. The gauges fell for the ninth straight day.

Bharti Airtel Ltd. (BHARTI IN) retreated 3.2 percent to 357.9 rupees, its biggest fall in more than three months. India’s largest mobile-phone operator said fourth-quarter profit fell 31 percent after higher costs for network and advertising expenses eroded margins.

Canara Bank (CBK IN) fell 2.6 percent to 558.65 rupees, its lowest close in more than two months. The lender posted a net income of 8.99 billion rupees in the fourth quarter, missing analysts’ estimates of 11.2 billion rupees.

Jyothy Laboratories Ltd. (JYL IN) soared 8.1 percent to 223.25 rupees, the steepest advance since June 18. A global private equity fund is likely to buy at least 26 percent stake in the household-products maker for about $150 million, the Economic Times reported today, citing people it didn’t identify. The company said the report was “speculative” in an exchange filing.

Kotak Mahindra Bank Ltd. (KMB IN) climbed 2.2 percent to 422 rupees, its steepest advance in more than two weeks. The lender, controlled by Indian billionaire Uday Kotak, posted a 17 percent increase in fourth-quarter net income, according to an exchange filing.

NTPC Ltd. (NTPC IN) decreased 2.6 percent to 173.95 rupees, its lowest in more than a month. India will cancel five coal mining leases alloted to the country’s largest power producer for “slow or non-implementation” of the projects, according to an e-mailed statement from the coal ministry today.

Piramal Life Sciences Ltd. (PLSL IN), a drug-research company, surged 9.9 percent to 104.1 rupees, its steepest climb in seven weeks. Piramal Healthcare Ltd. (PIHC IN), which owns 17.88 percent of the Piramal Life, will consider a proposal to merge a unit of the company with itself, according to an exchange filing. Piramal Healthcare fell 0.5 percent to 458.5 rupees.

Ranbaxy Laboratories Ltd. (RBXY IN) plunged 6 percent to 426.35 rupees, its lowest close in almost 11 months. U.S. federal prosecutors are negotiating a settlement with India’s largest drugmaker by revenue that could result in fines and payments exceeding $1 billion, Fortune magazine reported, citing people with knowledge of the talks. The company declined to comment, according to an e-mailed statement.

Reliance Industries Ltd. (RIL IN) rose 1.1 percent to 949.95 rupees, its highest advance in a week. India’s biggest listed firm by market value plans to invest as much as $12 billion in the chemicals business, the Economic Times reported, citing an interview with Chairman Mukesh Ambani. It will also increase output of natural gas from the KG-D6 block after analyzing data for a few more quarters with the help of BP Plc, the newspaper said. Manoj Warrier, a Reliance Industries spokesman, declined to comment on the report.

Sundaram Clayton Ltd. (SDC IN) advanced 2.3 percent to 153.6 rupees. The auto-part maker’s net income for the three months ended March 31 more than trebled to 157.1 million rupees, according to an exchange filing.

Thermax Ltd. (TMX IN) slid 3.5 percent to 591.75 rupees, its lowest close in more than a month. The power equipment maker, which fell for the fifth day, was cut to “sell” from “hold” at Citigroup Inc., which cited a “muted” outlook for order inflows. The brokerage reduced its share-price estimate to 542 rupees from 698 rupees, analysts led by Deepal Delivala wrote in a report.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.